Cannabis Use As a Factor of Lower Corpulence in Hepatitis C-infected Patients: Results from the ANRS CO22 Hepather Cohort

Overview

Journal J Cannabis Res

Date 2022 Jun 11

PMID 35690798

Authors

Tangui Barre

Fabrice Carrat

Clemence Ramier

Helene Fontaine

Vincent Di Beo

Morgane Bureau

Celine Dorival

Dominique Larrey

Elisabeth Delarocque-Astagneau

Philippe Mathurin

Fabienne Marcellin

Ventzislava Petrov-Sanchez

Carole Cagnot

Patrizia Carrieri

Stanislas Pol

Camelia Protopopescu

Affiliations

Soon will be listed here.

Abstract

Background: Patients with chronic hepatitis C virus (HCV) infection are at greater risk of developing metabolic disorders. Obesity is a major risk factor for these disorders, and therefore, managing body weight is crucial. Cannabis use, which is common in these patients, has been associated with lower corpulence in various populations. However, this relationship has not yet been studied in persons with chronic HCV infection.

Methods: Using baseline data from the French ANRS CO22 Hepather cohort, we used binary logistic and multinomial logistic regression models to test for an inverse relationship between cannabis use (former/current) and (i) central obesity (i.e., large waist circumference) and (ii) overweight and obesity (i.e., elevated body mass index (BMI)) in patients from the cohort who had chronic HCV infection. We also tested for relationships between cannabis use and both waist circumference and BMI as continuous variables, using linear regression models.

Results: Among the 6348 participants in the study population, 55% had central obesity, 13.7% had obesity according to their BMI, and 12.4% were current cannabis users. After multivariable adjustment, current cannabis use was associated with lower risk of central obesity (adjusted odds ratio, aOR [95% confidence interval, CI]: 0.45 [0.37-0.55]), BMI-based obesity (adjusted relative risk ratio (aRRR) [95% CI]: 0.27 [0.19-0.39]), and overweight (aRRR [95% CI]: 0.47 [0.38-0.59]). This was also true for former use, but to a lesser extent. Former and current cannabis use were inversely associated with waist circumference and BMI.

Conclusions: We found that former and, to a greater extent, current cannabis use were consistently associated with smaller waist circumference, lower BMI, and lower risks of overweight, obesity, and central obesity in patients with chronic HCV infection. Longitudinal studies are needed to confirm these relationships and to assess the effect of cannabis use on corpulence and liver outcomes after HCV cure.

Trial Registration: ClinicalTrials.gov identifier: NCT01953458 .

Citing Articles

Cannabis Use Is Inversely Associated with Metabolic Disorders in Hepatitis C-Infected Patients (ANRS CO22 Hepather Cohort).

Barre T, Bourliere M, Ramier C, Carrat F, Di Beo V, Protopopescu C J Clin Med. 2022; 11(20).

PMID: 36294456 PMC: 9605108. DOI: 10.3390/jcm11206135.

References

Barre T, Pol S, Ramier C, Di Beo V, Carrat F, Bureau M . Cannabis Use Is Inversely Associated with Overweight and Obesity in Hepatitis B Virus-Infected Patients (ANRS CO22 Hepather Cohort). Cannabis Cannabinoid Res. 2021; 7(5):677-689. PMC: 9587766. DOI: 10.1089/can.2021.0094. View

Pigeyre M, Rousseaux J, Trouiller P, Dumont J, Goumidi L, Bonte D . How obesity relates to socio-economic status: identification of eating behavior mediators. Int J Obes (Lond). 2016; 40(11):1794-1801. DOI: 10.1038/ijo.2016.109. View

Shai I, Jiang R, Manson J, Stampfer M, Willett W, Colditz G . Ethnicity, obesity, and risk of type 2 diabetes in women: a 20-year follow-up study. Diabetes Care. 2006; 29(7):1585-90. DOI: 10.2337/dc06-0057. View

Barre T, Nishimwe M, Protopopescu C, Marcellin F, Carrat F, Dorival C . Cannabis use is associated with a lower risk of diabetes in chronic hepatitis C-infected patients (ANRS CO22 Hepather cohort). J Viral Hepat. 2020; 27(12):1473-1483. DOI: 10.1111/jvh.13380. View

Chaudhari R, Fouda S, Sainu A, Pappachan J . Metabolic complications of hepatitis C virus infection. World J Gastroenterol. 2021; 27(13):1267-1282. PMC: 8015302. DOI: 10.3748/wjg.v27.i13.1267. View

Ross R, Neeland I, Yamashita S, Shai I, Seidell J, Magni P . Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity. Nat Rev Endocrinol. 2020; 16(3):177-189. PMC: 7027970. DOI: 10.1038/s41574-019-0310-7. View

OSullivan S, Yates A, Porter R . The Peripheral Cannabinoid Receptor Type 1 (CB) as a Molecular Target for Modulating Body Weight in Man. Molecules. 2021; 26(20). PMC: 8538448. DOI: 10.3390/molecules26206178. View

Vancsa S, Nemeth D, Hegyi P, Szakacs Z, Farkas A, Kiss S . Diabetes Mellitus Increases the Risk of Hepatocellular Carcinoma After Direct-Acting Antiviral Therapy: Systematic Review and Meta-Analysis. Front Med (Lausanne). 2021; 8:744512. PMC: 8558240. DOI: 10.3389/fmed.2021.744512. View

Younossi Z, McCullough A, Ong J, Barnes D, Post A, Tavill A . Obesity and non-alcoholic fatty liver disease in chronic hepatitis C. J Clin Gastroenterol. 2004; 38(8):705-9. DOI: 10.1097/01.mcg.0000135372.10846.2a. View

10.

Freeman T, Craft S, Wilson J, Stylianou S, ElSohly M, Di Forti M . Changes in delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) concentrations in cannabis over time: systematic review and meta-analysis. Addiction. 2020; 116(5):1000-1010. DOI: 10.1111/add.15253. View

11.

Pol S, Bourliere M, Lucier S, Hezode C, Dorival C, Larrey D . Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients. J Hepatol. 2016; 66(1):39-47. DOI: 10.1016/j.jhep.2016.08.021. View

12.

Cluny N, Keenan C, Reimer R, Le Foll B, Sharkey K . Prevention of Diet-Induced Obesity Effects on Body Weight and Gut Microbiota in Mice Treated Chronically with Δ9-Tetrahydrocannabinol. PLoS One. 2015; 10(12):e0144270. PMC: 4669115. DOI: 10.1371/journal.pone.0144270. View

13.

Spindle T, Kuwabara H, Eversole A, Nandi A, Vandrey R, Antoine D . Brain imaging of cannabinoid type I (CB ) receptors in women with cannabis use disorder and male and female healthy controls. Addict Biol. 2021; 26(6):e13061. PMC: 8516687. DOI: 10.1111/adb.13061. View

14.

Russo E . The Case for the Entourage Effect and Conventional Breeding of Clinical Cannabis: No "Strain," No Gain. Front Plant Sci. 2019; 9:1969. PMC: 6334252. DOI: 10.3389/fpls.2018.01969. View

15.

Alam I, Ullah N, Alam I, Ali I . The effects and underlying mechanism of interferon therapy on body weight and body composition. Pak J Pharm Sci. 2013; 26(6):1251-7. View

16.

Asselah T, Estrabaud E, Bieche I, Lapalus M, De Muynck S, Vidaud M . Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin. Liver Int. 2010; 30(9):1259-69. PMC: 3071938. DOI: 10.1111/j.1478-3231.2010.02283.x. View

17.

Jing L, Zhang Y, Fan S, Gu M, Guan Y, Lu X . Preventive and ameliorating effects of citrus D-limonene on dyslipidemia and hyperglycemia in mice with high-fat diet-induced obesity. Eur J Pharmacol. 2013; 715(1-3):46-55. DOI: 10.1016/j.ejphar.2013.06.022. View

18.

Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-Venier V . FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology. 2007; 46(1):32-6. DOI: 10.1002/hep.21669. View

19.

Graczyk M, Lewandowska A, Dzierzanowski T . The Therapeutic Potential of Cannabis in Counteracting Oxidative Stress and Inflammation. Molecules. 2021; 26(15). PMC: 8347461. DOI: 10.3390/molecules26154551. View

20.

Patsenker E, Sachse P, Chicca A, Gachet M, Schneider V, Mattsson J . Elevated levels of endocannabinoids in chronic hepatitis C may modulate cellular immune response and hepatic stellate cell activation. Int J Mol Sci. 2015; 16(4):7057-76. PMC: 4425004. DOI: 10.3390/ijms16047057. View